From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations
Top Cited Papers
Open Access
- 1 February 2016
- journal article
- Published by American Society for Cell Biology (ASCB) in Molecular Biology of the Cell
- Vol. 27 (3), 424-433
- https://doi.org/10.1091/mbc.e14-04-0935
Abstract
More than 2000 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) have been described that confer a range of molecular cell biological and functional phenotypes. Most of these mutations lead to compromised anion conductance at the apical plasma membrane of secretory epithelia and cause cystic fibrosis (CF) with variable disease severity. Based on the molecular phenotypic complexity of CFTR mutants and their susceptibility to pharmacotherapy, it has been recognized that mutations may impose combinatorial defects in CFTR channel biology. This notion led to the conclusion that the combination of pharmacotherapies addressing single defects (e.g., transcription, translation, folding, and/or gating) may show improved clinical benefit over available low-efficacy monotherapies. Indeed, recent phase 3 clinical trials combining ivacaftor (a gating potentiator) and lumacaftor (a folding corrector) have proven efficacious in CF patients harboring the most common mutation (deletion of residue F508, ΔF508, or Phe508del). This drug combination was recently approved by the U.S. Food and Drug Administration for patients homozygous for ΔF508. Emerging studies of the structural, cell biological, and functional defects caused by rare mutations provide a new framework that reveals a mixture of deficiencies in different CFTR alleles. Establishment of a set of combinatorial categories of the previously defined basic defects in CF alleles will aid the design of even more efficacious therapeutic interventions for CF patients.Keywords
This publication has 94 references indexed in Scilit:
- Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lungNature, 2012
- Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and FunctionCell, 2012
- Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved SequencesCell, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Loss of Anion Transport without Increased Sodium Absorption Characterizes Newborn Porcine Cystic Fibrosis Airway EpitheliaCell, 2010
- A Stabilizing Influence: CAL PDZ Inhibition Extends the Half‐Life of ΔF508‐CFTRAngewandte Chemie-International Edition, 2010
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutationNew England Journal of Medicine, 2010
- Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosisNature Chemical Biology, 2009
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proceedings of the National Academy of Sciences, 2009
- PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR -G542X nonsense allele in a CF mouse modelProceedings of the National Academy of Sciences, 2008